Evidence map›Paper›PMID 30691026›Full record

ArticleGenes2019

Analysis of the Association Between

Daniela Scarabino, Martina Peconi, Franca Pelliccia, Rosa Maria Corbo

Open access · goldAbstract read
In one paragraph

Article in Genes, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
1.6field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 19 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Mechanism ofEvidence-based complementary and alternative medicine : eCAM · 2022
    Article
  9. Polymorphic tandem DNA repeats activate the human telomerase reverse transcriptase gene.Proceedings of the National Academy of Sciences of the United States of America · 2021
    Article
  10. Heritable variation in telomere length predicts mortality in Soay sheep.Proceedings of the National Academy of Sciences of the United States of America · 2021
    Article
  11. Article
  12. Review
  13. Review
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 1 country.

Daniela ScarabinoCNR Institute of Molecular Biology and Pathology, P.le Aldo Moro 5, 00185 Rome, Italy. daniela.scarabino@cnr.it.
Martina PeconiCNR Institute of Translational Pharmacology, Via Fosso del Cavaliere 100, 00133 Rome, Italy. martinapeconi@gmail.com.
Franca PellicciaDepartment of Biology and Biotechnology, La Sapienza University, P.le Aldo Moro 5, 00185 Rome, Italy. franca.pelliccia@uniroma1.it.
Rosa Maria CorboCNR Institute of Molecular Biology and Pathology, P.le Aldo Moro 5, 00185 Rome, Italy. rosamaria.corbo@uniroma1.it.
Institute of Molecular Biology and Pathology · ITIstituto di Farmacologia Traslazionale · ITSapienza University of Rome · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We investigated the possible influence of TERC and TERT genetic variation and leukocyte telomere length (LTL) on human lifespan. Four polymorphisms of TERT and three polymorphisms of TERC were examined in a sample of elderly subjects (70⁻100 years). After nine years of follow-up, mortality data were collected, and sub-samples of long-lived/not long-lived were defined. TERT VNTR MNS16A L/L genotype and TERT rs2853691 A/G or G/G genotypes were found to be associated with a significantly higher risk to die before the age of 90 years, and with a significantly lower age at death. The association between lifespan and LTL at baseline was analyzed in a subsample of 163 subjects. Age at baseline was inversely associated with LTL (p < 0.0001). Mean LTL was greater in the subjects still living than in those no longer living at follow-up (0.79 T/S ± 0.09 vs 0.63 T/S ± 0.08, p < 0.0001). Comparison of age classes showed that, among the 70⁻79-year-olds, the difference in mean LTL between those still living and those no longer living at follow-up was greater than among the 80⁻90-year-olds. Our data provide evidence that shorter LTL at baseline may predict a shorter lifespan, but the reliability of LTL as a lifespan biomarker seems to be limited to a specific age (70⁻79 years).

Indexed as

Polymorphism, Single NucleotideAgedAged, 80 and overFemaleHumansLongevityMaleMicrosatellite RepeatsRNATelomeraseTelomere HomeostasisRNATelomerasetelomerase RNATERT protein, humangenetic variationhuman lifespanleukocyte telomere lengthTERCTERT

Identifiers

PMID30691026
PMCPMC6409517
OpenAlexW2911727661

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.